DVA

DaVita HealthCare fell 1.32% on October 23, 2026, underperforming the S&P 500's 0.52% decline. Despite the daily drop, DVA has gained 6.54% over the past month, outpacing the Medical sector's 3.23% gain.

The company is expected to report earnings on October 29 with projected EPS of $3.78 (up 50.60% YoY) and revenue of $3.53 billion (up 3.23% YoY). DVA trades at a Forward P/E of 12.77, below the industry average of 20.58, and holds a Zacks Rank of #3 (Hold).

DaVita (DVA) shares have gained 55.6% year-to-date, outpacing industry growth, driven by better operating execution, improved treatment-volume outlook, and growing confidence in value-based kidney care. The company reaffirmed 2026 guidance with expected earnings growth of 50.6% on 3.2% sales growth, supported by higher revenue per treatment and labor productivity gains. However, risks include insurance-mix headwinds from ACA subsidy losses, rising patient-care costs, and uncertain Medicare reimbursement policies.

DaVita HealthCare (DVA) closed at $187.25, down 1.01% in the latest session but outperforming the S&P 500's 1.09% decline. The kidney dialysis provider is forecasted to report EPS of $3.78 (up 50.6% YoY) with revenue expected at $3.53 billion (up 3.23% YoY).

Trading at a Forward P/E of 12.98 versus the industry average of 20.96, DVA appears undervalued. The stock holds a Zacks Rank #3 (Hold) with a PEG ratio of 0.49, significantly below the industry average of 1.82.

DaVita HealthCare (DVA) closed at $179.25, up 1.26% and outperforming the S&P 500. The kidney dialysis provider is projected to report 50.6% EPS growth and 3.23% revenue growth in the upcoming quarter, with full-year estimates showing 35.16% earnings growth. Trading at a Forward P/E of 12.15 (below industry average of 20.06) and a PEG ratio of 0.46, DVA holds a Zacks Rank #3 (Hold) rating.

DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market.

DaVita HealthCare (DVA) closed at $178.69, up 1.33%, outperforming the S&P 500's 0.73% gain. The kidney dialysis provider is projected to report earnings of $3.78 per share with 50.6% year-over-year growth. The stock trades at a Forward P/E of 12.1, below the industry average of 19.68, and holds a Zacks Rank of #3 (Hold) with a PEG ratio of 0.46, indicating potential value.

Option Care Health (OPCH) surged 32.7% following the announcement of its acquisition by CD&R and McKesson for $32.05 per share in cash, representing a 37% premium to the previous closing price. The $5.8 billion enterprise value deal underscores the strategic appeal of OPCH's home and alternate-site infusion care platform. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that sustained momentum may depend on future estimate trends.